If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USADepartment of Otolaryngology, University of Michigan, Ann Arbor, Michigan, USADepartment of Surgery, University of Michigan, Ann Arbor, Michigan, USA
Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USADepartment of Cell and Developmental Biology, University of Michigan, Ann Arbor, Michigan, USA
Merkel cell carcinoma (MCC) is a rare and deadly neuroendocrine skin tumor frequently associated with clonal integration of a polyomavirus, Merkel cell polyomavirus (MCPyV), and MCC tumor cells express putative polyomavirus oncoprotein small T antigen (sTAg) and truncated large T antigen. Here, we show robust transforming activity of sTAg in vivo in a panel of transgenic mouse models. Epithelia of preterm sTAg-expressing embryos exhibited hyperplasia, impaired differentiation, increased proliferation, and apoptosis, and activation of a DNA damage response. Epithelial transformation did not require sTAg interaction with the protein phosphatase 2A protein complex, a tumor suppressor in some other polyomavirus transformation models, but was strictly dependent on a recently described sTAg domain that binds Fbxw7, the substrate-binding component of the Skp1/Cullin1/F-box protein ubiquitin ligase complex. Postnatal induction of sTAg using a Cre-inducible transgene also led to epithelial transformation with development of lesions resembling squamous cell carcinoma in situ and elevated expression of Fbxw7 target proteins. Our data establish that expression of MCPyV sTAg alone is sufficient for rapid neoplastic transformation in vivo, implicating sTAg as an oncogenic driver in MCC and perhaps other human malignancies. Moreover, the loss of transforming activity following mutation of the sTAg Fbxw7 binding domain identifies this domain as crucial for in vivo transformation.
Abbreviations
CC3
cleaved caspase 3
GFP
green fluorescent protein
K5
keratin 5
LSD
large T stabilization domain
LTAg
large T antigen
MCC
Merkel cell carcinoma
MCPyV
Merkel cell polyomavirus
PP2A
protein phosphatase 2A
RFP
red fluorescent protein
SCC
squamous cell carcinoma
SCF
Skp1/Cullin1/F-box protein
sTAg
small T antigen
tLTAg
truncated large T antigen
INTRODUCTION
Merkel cell carcinoma (MCC) is a rare and deadly neuroendocrine malignancy that arises primarily in the skin (
). Although MCC can be cured at early stages, the 5-year relative survival rate of patients with lymph node involvement is 39%, and a mere 18% for those individuals with distant metastases (
Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system.
The lack of effective treatments for advanced MCC has fueled studies into the molecular basis of MCC with the hope of identifying new targets for therapy. A pivotal report by Moore and coworkers identified a novel polyomavirus, named Merkel cell polyomavirus (MCPyV), in 8 of 10 human MCC samples by digital transcriptome subtraction (
). Polyomaviruses are double-stranded DNA viruses that include murine polyomavirus, simian virus 40, and at least 12 human polyomaviruses, including MCPyV and several other polyomaviruses identified specifically in the skin (
), strongly suggesting that this virus is present at tumor initiation and that one or more viral proteins function as oncogenic drivers. Similar to that of other polyomaviruses, the MCPyV genome contains an early region with genes encoding the putative transforming antigens large T (LTAg) and small T (sTAg) and a late region with genes encoding the viral capsid components (
). MCPyV-positive tumor cells express sTAg and LTAg with tumor-specific C-terminal truncations (truncated LTAg, tLTAg), which disrupt viral helicase activity but retain the consensus domain for binding to the retinoblastoma 1 (RB1) tumor suppressor protein (
). TAgs from other polyomaviruses contribute to transformation and tumorigenesis by interacting with key cellular factors: most LTAgs disrupt the function of RB1 and TP53 tumor suppressors, whereas sTAgs inhibit the protein phosphatase 2A (PP2A) tumor suppressor complex (
). In general, LTAg is the dominant transforming oncogene for most polyomaviruses, and sTAg either does not transform or does so with low efficiency but cooperates to mediate the full transformation potential of LTAg (reviewed in
MCPyV sequences have been detected in various tumor types other than MCC, but the significance of these findings is unclear in light of the widespread prevalence of this virus in the general population, the generally low virus copy number in non-MCC tumors, and detection of MCPyV sequences in normal tissues as well as cancer tissues. Interestingly, a small number of MCPyV-positive cases of chronic lymphocytic leukemia and non–small-cell lung cancer harbor tumor-specific LTAg mutations and express LTAg protein (
), in keeping with a functional role for MCPyV in the development of tumors other than MCC.
Genetic knockdown of tLTAg and sTAg, or either tLTAg or sTAg alone, leads to reduced proliferation of MCC cell lines and/or tumor xenografts, arguing that TAg expression is required for maintenance of cultured MCC tumor cells (
) had no effect on tumor cell proliferation or viability in vitro, raising the possibility that in some cases, MCPyV may lead to tumor development through a hit-and-run mechanism (reviewed in
). In contrast to TAgs from other polyomaviruses, in vitro studies revealed that MCPyV sTAg, and not LTAg, is capable of driving a transformed phenotype in rodent fibroblasts (
) but does require a domain that binds Fbxw7 and leads to accumulation of several cellular oncoproteins and LTAg, designated the LT-stabilization domain (LSD;
) have set the stage for in vivo analysis of MCPyV TAg transforming potential, which we have now examined using a panel of transgenic mice carrying wild-type or mutant sTAgs. We show that expression of sTAg in preterm embryos is sufficient for transformation of several epithelia including the skin. The phenotypes are independent of PP2A binding but strictly dependent on the recently described sTAg LSD. In adult mice, sTAg drives rapid epidermal hyperplasia and development of skin lesions resembling squamous cell carcinoma (SCC) in situ. Our findings identify sTAg as a powerful oncogenic driver in vivo, support the concept that MCPyV may have a role in the development of tumors other than MCC, and establish a strict requirement for the sTAg LSD for epithelial transformation in mice.
RESULTS
Epithelial transformation in transgenic mouse embryos expressing MCPyV sTAg
We used a transgenic cassette with 5.3 kb bovine keratin 5 (K5) promoter (
) to target expression of sTAg to the epidermis and several other epithelia. We constructed the K5-sTAg transgene with an internal ribosomal entry site (IRES) and tdTomato complementary DNA (cDNA) downstream of sTAg, enabling us to use immunostaining for red fluorescent protein (RFP; tdTomato) as an indicator of transgene expression (Figure 1a, Supplementary Table S1 online). As we could not predict the biological response of K5-targeted cells to sTAg expression, we analyzed preterm transgenic embryos to circumvent a potentially severe phenotype incompatible with postnatal survival. Histology of K5-sTAg embryos revealed striking alterations in several epithelia where the K5 promoter was active, including the skin, tongue, palate, tooth primordia, and salivary glands (Figure 1b, Supplementary Table S1 online). The most severe changes were detected in acral skin and oral cavity and typically included the replacement of differentiated epithelial cell layers by an expanded and disorganized epithelium (Figure 1b). Mitotic cells, largely restricted to the basal and first suprabasal layer in control epithelia, were detected in mid and upper cell layers in K5-sTAg mice, and condensed or fragmented nuclei suggestive of apoptosis were frequently observed, typically limited to the uppermost strata of affected epithelia (Figure 1b). Similar changes were seen in multiple independent transgenic founders (Supplementary Table S1 online).
Figure 1Epithelial transformation in preterm mouse embryo expressing MCPyV sTAg. (a) Transgenic cassette including bovine keratin 5 (K5) promoter, wild-type Merkel cell polyomavirus (MCPyV) small T antigen (sTAg), and internal ribosomal entry site (IRES)-tdTomato (RFP), designated K5-sTAg. (b) Histology of indicated epithelia from preterm control and K5-sTAg embryos. Rectangles indicate regions shown at higher magnification. Note: increased thickness of epithelia in K5-sTAg mice and loss or reduction of differentiated granular (white asterisk) and cornified (black asterisk) cell layers seen in controls. White arrowheads indicate pyknotic nuclei with condensed chromatin suggestive of apoptosis in K5-sTAg epithelia; black arrowheads identify suprabasal mitotic figures, which are normally restricted to basal or immediate suprabasal cell layers. Scale bars=25 μm.
MCPyV sTAg drives alterations in epithelial differentiation, proliferation, and apoptosis
Immunostaining for RFP showed a strong correlation between transgene expression and epithelial abnormalities. RFP was not detected or was only present in a small number of cells in K5-sTAg mice that lacked any apparent phenotypic changes (Supplementary Table S1 online). In contrast, in embryos with dysplastic epithelia, RFP was frequently expressed throughout multiple cell layers (Figure 2a). Analysis of epithelial lineage markers revealed an altered program of terminal differentiation. Cells expressing K5, normally limited to the basal and lower suprabasal cell layers, were detected in suprabasal strata of the epidermis and tongue in K5-sTAg mice (Figure 2b). In contrast, the number of cell layers expressing the late-stage epidermal differentiation marker loricrin was reduced (Figure 2b). In some areas, the outermost cellular compartment in the epidermis, the stratum corneum, was also reduced in thickness (Figures 1b and 2a).
Figure 2MCPyV sTAg alters epithelial differentiation, proliferation, and apoptosis. (a) Hematoxylin and eosin (H&E) and red fluorescent protein (RFP) immunostaining of acral skin and tongue showing disorganized, hyperplastic epithelia, and widespread transgene (RFP) expression. (b) Expansion of the basal layer marker keratin 5 (K5) and impaired expression of the granular cell marker loricrin in sTAg-expressing epithelia. (c) Striking upward expansion of Ki67-expressing proliferating cells and phospho-histone H3 (pHH3)-expressing mitotic cells in sTAg-expressing epidermis. (d) Immunostaining for the apoptosis marker CC3 and DNA damage response marker γH2AX in sTAg epidermis. Scale bars=25 μm.
There was a marked expansion of cells expressing the proliferation markers Ki67 and pHH3 in affected epithelia (Figure 2c), and many cells expressed the apoptosis marker cleaved caspase 3 (CC3), particularly in the upper strata (Figure 2d). Expression of γH2AX, an indicator of DNA damage frequently detected in cancer (
), was also elevated in epithelia of K5-sTAg mice (Figure 2d). In mosaic founders (Supplementary Table S1 online), the above alterations were largely limited to RFP-expressing cells, indicating that these epidermal responses to sTAg are largely cell autonomous. Collectively, these data establish that expression of MCPyV sTAg in vivo is sufficient to produce multiple phenotypic alterations that are associated with epithelial neoplasia.
In vivo transformation by MCPyV sTAg is not dependent on interaction with PP2A
To begin testing for a potential mechanism regulating sTAg’s potent transforming activity in vivo, we first focused on the PP2A tumor suppressor complex (
). We modified the K5-sTAg cassette to yield a mutant sTAg carrying a leucine to alanine substitution at amino acid 142 (sTAgL142A) (Figure 3a), which disrupts interaction with both the Aα structural subunit and catalytic C subunit of PP2A (
). The phenotype of K5-sTAgL142A mice was similar to that of K5-sTAg mice (Figure 3b, Supplementary Figure S1A and Table S1 online) and included impaired differentiation, an expanded proliferative compartment, and nuclear fragmentation (Figure 3b). Immunostaining revealed an increased proportion of Ki67-expressing cells, impaired differentiation, increased apoptosis, and expression of γH2AX (Supplementary Figure S1A online). These data argue that binding of sTAg to the PP2A tumor suppressor is not required for in vivo transformation in epithelia.
Figure 3Epithelial transformation by a protein phosphatase 2A (PP2A) binding–deficient sTAg mutant. (a) Keratin 5 (K5)-sTAgL142A transgene construction identical to K5-sTAg in Figure 1a, except for L142A substitution, which blocks sTAg binding to PP2A. (b) Hematoxylin and eosin and RFP immunostaining in sections from acral skin, tongue, and palate, showing features of transformation similar to those in K5-sTAg mice and robust transgene expression. RFP immunostaining is shown in insets. Scale bars=50 μm.
In vivo transformation by sTAg is strictly dependent on the LSD which binds Fbxw7
In contrast to the PP2A binding domain, the sTAg LSD is essential for transformation in cultured cells. Mutant sTAg with alanine substitutions at amino acids 91–95, which no longer co-immunoprecipitates with overexpressed Fbxw7 (
), prevents accumulation of LTAg and several cellular targets and fails to transform fibroblasts. To test the in vivo transforming potential of this LSD mutant, we generated a K5-sTAg91–95A transgenic construct (Figure 4a) and produced additional transgenic embryos. Strikingly, histology of the epidermis from K5-sTAg91–95A preterm embryos was indistinguishable from that of controls (Figure 4b), and immunostaining to detect a panel of epidermal markers, Ki67, CC3, and γH2AX, supported this impression (Figure 4c). RFP expression confirmed robust transgene expression in epidermal basal cells where the K5 promoter is active under normal conditions (Figure 4b). Thus, in striking contrast to the robust in vivo transforming potential of wild-type or PP2A binding–deficient sTAg, the sTAg LSD mutant fails to drive epithelial transformation in preterm embryos.
Figure 4Lack of epithelial transformation by an LSD sTAg mutant. (a) Transgene construction identical to K5-sTAg in Figure 1a, except for 91–95A substitutions, which block sTAg binding to Fbxw7. (b) Similar histology of acral skin and tongue in sections from control and K5-sTAg91-95A transgenic mice, despite robust RFP expression in basal layer cells of transgenic mice. (c) Similar profile of epidermal markers and proliferation and lack of CC3 and γH2AX immunostaining in control and K5-sTAg91–95A transgenic acral skin. Scale bars=50 μm. H&E, hematoxylin and eosin; K5, keratin 5; LTAg, large T antigen; RFP, red fluorescent protein; sTAg, small T antigen.
Postnatal activation of MCPyV sTAg leads to epidermal transformation and squamous cell carcinoma in situ
To assess the transforming potential of sTAg in adult mice, we engineered Cre-inducible sTAg transgenic mice, designated KLEsT, using a modified K5 construct (
) that contains a floxed enhanced GFP/STOP sequence upstream of the sTAg cDNA (Figure 5a). KLEsT mice express green fluorescent protein (GFP) in K5-expressing cells, but, in the presence of Cre, recombination at the loxP sites leads to deletion of the GFP/STOP sequence and transcription of the previously dormant sTAg cDNA (Figure 5a). We crossed KLEsT mice with K5-CreERT2 mice (
Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen- inducible Cre-ER(T) and Cre-ER(T2) recombinases.
) carrying a tamoxifen-inducible Cre to generate K5-CreERT2;KLEsT (iK5;KLEsT) bitransgenic mice. Treatment of these mice with tamoxifen to activate sTAg expression led to profound alterations in the epidermis at several body sites including tail, ear, snout, and volar skin (Figure 5b and c). Affected epidermis was markedly hyperplastic, with the most striking changes in ear epidermis, which was over 10-fold thicker than in control mice (P<0.001; Figure 5d). Cells with condensed or fragmented nuclei were common and epidermal maturation was altered in some areas, with the absence of a granular cell layer, abrupt keratinization, and regions of prominently thickened stratum corneum containing retained nuclei (parakeratosis; Figure 5b). In some areas, the histological changes were more advanced and included full-thickness atypia, reduced eosin staining, pyknotic nuclei, and tissue disorganization, which collectively recapitulate many features of human SCC in situ (Bowen’s disease; Figure 5e). We detected sTAg in iK5;KLEsT mice exhibiting a strong epidermal phenotype using immunoprecipation followed by immunoblotting of skin lysates with the 2t2 mAb (
Figure 5Postnatal activation of sTAg induces epidermal transformation in adult mice. (a) Design of KLEsT transgene expressing eGFP and dormant sTAg, in which Cre-mediated recombination and GFP excision allow keratin 5 (K5)-driven sTAg expression. (b, c) Phenotype of K5-CreER;KLEsT (iK5;KLEsT) bitransgenic mice 2–3 weeks post tamoxifen treatment at P21. Note massive epidermal hyperplasia, disorganized stratification, suprabasal mitoses (arrowheads), and hyperkeratotic regions (asterisk). (d) Quantification of increased epidermal thickness at indicated sites (N=3 for each column, error bars indicate SEM, **P<0.005, ***P<0.0003). (e) Similarity of iK5;KLEsT epidermal phenotype and human SCC in situ. Both lesions show a severely disorganized epithelium, pale-staining atypical epidermal cells (arrowheads), apoptotic cells (arrows), and hyperkeratosis (asterisk). (f) Expression of sTAg in lysates from iK5;KLEsT mice collected 11 days (snout) and 21 days (tail) after tamoxifen treatment. sTAg was detected by immunoprecipitation and immunoblotting using 2t2 monoclonal Ab. Scale bars=50 μm.
Immunostaining of the skin from adult sTAg-expressing mice revealed expansion of Ki67-expressing cells and an increased number of cells expressing CC3 and γH2AX (Figure 6a), reflecting changes we detected in preterm K5-sTAg embryos. Immunostaining for lineage markers again revealed an expanded population of cells expressing K5 and the appearance of hyperplasia-associated keratins K6 and K17 (Figure 6b and c). Occasionally, expression of the granular cell marker loricrin and spinous cell marker K10 was focally reduced or absent beneath regions of parakeratosis (Figure 6b). Although K20, K8, and synaptophysin were easily detected in normal Merkel cells, these markers were not appreciably induced in hyperplastic regions of the epidermis from iK5;KLEsT mice (Supplementary Figure S2 online). Postnatal activation of sTAg in cutaneous epithelia thus mimics many of the changes seen in transgenic embryos, and in some areas leads to lesions closely resembling human SCC in situ, but expression of sTAg alone does not appear to be sufficient to drive epidermal cells into the Merkel cell lineage.
Figure 6Postnatal activation of sTAg induces markers of epidermal transformation and accumulation of Fbxw7 target proteins. (a) Expansion of proliferative cell layers (Ki67), increased apoptosis (cleaved caspase 3; CC3), and DNA damage (γH2AX) in tail epidermis of sTAg-expressing iK5;KLEsT mice 3 weeks after treatment with tamoxifen. (b) Expansion of cell layers expressing keratin 5 (K5) and focal reductions in expression of the differentiation markers K10 and loricrin. (c) Upregulation of hyperplasia-associated keratins K6 and K17 in the epidermis of iK5;KLEsT mice. Normal expression of these keratins is largely restricted to the hair follicle. (d) Immunoblotting for Fbwx7 targets, proliferating cell nuclear antigen (PCNA), K17, and GFP in sets of snout lysates from control and iK5;KLEsT mice, collected 24 days (left panels) or 28 days (right panels) after tamoxifen treatment. Loss of GFP expression confirms efficient recombination of the KLEsT transgene. Scale bars=50 μm.
) and epithelial transformation in vivo (Figure 4) and is proposed to function at least in part by stabilizing LTAg and cellular proteins targeted for destruction by the Skp1/Cullin1/F-box (SCF)/Fbxw7 ubiquitin ligase complex (
). We therefore performed immunoblotting to assess whether epidermal transformation in adult mice was associated with accumulation of Fbxw7 targets. Expression levels of cyclin E, c-Jun, mTOR, and Mcl-1, all of which are Fbxw7 substrates targeted for destruction by the SCF/Fbxw7 complex (
), were elevated in skin lysates of iK5;KLEsT mice relative to controls (Figure 6d). Increased expression of proliferating cell nuclear antigen and K17 confirmed a hyperplastic response and loss of GFP indicated efficient recombination of the KLEsT transgene. These data are in keeping with the idea that binding of sTAg to Fbxw7 impairs its ability to target key cellular proteins for ubiquitin-mediated degradation, leading to their accumulation and potential contribution to sTAg-driven transformation.
DISCUSSION
The discovery of clonally integrated MCPyV viral sequences in the majority of human MCCs argues that MCPyV TAgs have a causal role in tumor development. We now present studies examining the tumorigenic potential of sTAg when expressed in vivo in preterm transgenic mouse embryos and adult mice. sTAg expression can promote neoplastic transformation in epithelia of late-stage mouse embryos in a PP2A-independent and sTAg LSD–dependent manner, whereas activation of sTAg in the skin of adult mice leads to similar transformation-related changes and also drives the development of lesions resembling SCC in situ. These findings establish sTAg as a potent oncogene in vivo and suggest that it functions as an oncogenic driver in MCC and potentially other cancers linked to MCPyV. The strict requirement for the Fbxw7-binding LSD region in epithelial transformation of preterm embryos, coupled with the upregulation of multiple oncogenic Fbxw7 targets in adult mice expressing sTAg, suggests that sTAg-Fbxw7 binding and stabilization of key cellular substrates may contribute to sTAg-driven epithelial transformation in vivo.
Epithelial abnormalities in preterm K5-sTAg embryos exhibit features in common with many neoplasms, including altered differentiation, an expanded proliferative compartment, increased apoptosis, and a robust DNA damage response. To delineate the potential mechanism by which sTAg drives these profound alterations in cell and tissue function, we analyzed the response to sTAg mutants defective in binding to either the tumor suppressor PP2A (sTAgL142A) or Fbxw7 (sTAg91-95A), the substrate-binding component of the SCF ubiquitin ligase complex, which has tumor suppressor activity in a broad range of malignancies (reviewed in
). We found that the PP2A binding site of sTAg is not required for epithelial transformation in preterm embryos, in keeping with results obtained using cultured fibroblasts (
); moreover, the expression of several Fbwx7 substrates is elevated in the skin of adult mice expressing wild-type sTAg. These data suggest that sTAg drives transformation in vivo, at least in part, via upregulation of cellular proteins targeted for destruction by the SCF/Fbxw7 complex. However, it is unlikely that the loss of transforming potential of the sTAg91–95A LSD mutant is solely due to disruption of normal Fbwx7 function, as Fbwx7 knockdown failed to fully restore fibroblast transformation by the sTAg91–95A LSD mutant (
). Further studies will be required to define additional functions that are disrupted in the sTAg91–95A LSD mutant, which may contribute to, or have a central role in, transformation.
The development of SCC in situ in adult mice expressing sTAg raises the possibility that MCPyV has a role in the development of other skin tumors or perhaps extracutaneous malignancies. In keeping with this possibility, MCPyV sequences have been detected in a few cases of chronic lymphocytic leukemia and non–small-cell lung cancer, which harbor tumor-specific LTAg truncations and express tLTAg protein (
). Of potential relevance to our findings in adult mice, one study documented MCPyV mutations that would yield tumor-specific LTAg truncation in human SCCs (
), although viral integration and copy number were not examined. Unfortunately, immunoreagents to selectively detect MCPyV sTAg are not readily available; hence, with the exception of a single report (
), immunostaining for TAg protein expression in MCPyV-positive tumors has been limited to LTAg or tLTAg.
Although the striking phenotypes seen in embryos and adult sTAg-expressing mice establish the transforming potential of sTAg expressed in epithelial cells, we did not detect lesions resembling MCC either morphologically or biochemically by immunostaining for a panel of MCC markers. Expression of sTAg alone in K5-expressing epidermal cells is thus not sufficient to drive MCC development in the context of this type of mouse model. This raises questions about the potential requirement for tLTAg and/or additional somatic mutations in MCC pathogenesis. As both sTAg and tLTAg appear to be coexpressed in most MCPyV-positive MCCs and tLTAg is required for MCC tumor cell maintenance, it seems likely that tLTAg has an important role in MCC tumorigenesis. Tumor-specific LTAg truncations are always downstream of the domain that binds the tumor suppressor RB1, which may be a critical cellular target for MCPyV, as it is in human papillomavirus–associated cancer. In keeping with this concept, MCCs that are MCPyV-negative have either lost or reduced endogenous RB1 expression (
The absence of MCCs in sTAg-expressing mice may also be related to the fact that our modeling strategy does not target transgene expression to a cell population competent to give rise to MCC. The potential cell of origin of MCC is controversial and may include epidermal cells, Merkel cell progenitors residing in the epidermis, or even differentiated Merkel cells. Expression of the epithelial marker p63 in MCC (
) is in keeping with the idea that at least some MCCs are derived from epidermal basal cells or Merkel cell progenitors, which co-express epidermal and Merkel cell markers. Additional modeling studies, testing the tumorigenic potential of sTAg alone or combined with tLTAg, will be required to assess whether expression of MCPyV TAgs in appropriate progenitor cells is sufficient to drive MCC development in mice.
In summary, we have utilized a powerful transgenic mouse embryo screening assay, coupled with Cre-inducible mouse lines for postnatal transgene induction, to establish that MCPyV sTAg has robust transforming activity in vivo. Our data suggest that sTAg functions as an oncogenic driver in MCC and perhaps other MCPyV-associated human tumors and may provide an important target for drug development. Future studies will focus on identifying the mechanism by which sTAg drives transformed phenotypes in vivo, and ascertaining whether combined expression of MCPyV sTAg and tLTAg in defined cell populations in the skin can give rise to murine tumors resembling human MCCs.
MATERIALS AND METHODS
Generation of transgenic mice
The K5-sTAg-IRES-tdTomato (K5-sTAg) transgenic cassette was generated as follows: a sTAg cDNA sequence (GenBank EU375803; nts 196–756) including an additional upstream Kozak sequence, a 5′ NotI site, and a 3′ SnaBI site was synthesized de novo by GenScript USA (Piscataway, NJ) and cloned into the pUC57 vector. A NotI-sTAg-SnaBI digested fragment was then subcloned into the pBK5 vector (
) containing an IRES-tdTomato sequence synthesized and subcloned by GenScript USA based on the pLVX-IRES-tdTomato vector (Clontech, cat# 631238; nts 2842–4847). Site directed mutagenesis using the GENEART Site-Directed Mutagenesis System (Life Technologies, Grand Island, NY) was used to create a leucine to alanine substitution at amino acid 142 to generate the K5-sTAgL142A cassette. The K5-sTAg91–95A cassette was generated with a nucleotide sequence substituting amino acid residues 91–95 with alanines (
) by GenScript USA using site directed mutagenesis. Following sequence verification, BssHII-digested fragments of each of the above constructs were purified and injected into (C57BL/6 X SJL) F2 mouse eggs in the University of Michigan Transgenic Core. The inducible K5-loxP-eGFP-loxP-sTAg (KLEsT) transgenic cassette was subcloned by GenScript USA using the pUC57-sTAg vector described above into a SnaBI-blunt restriction digested K5-loxP-eGFP-loxP (
To avoid loss of transgenic founders with lethal phenotypes, preterm embryos from all conventional K5 driven transgenic mice were harvested at e18.5 and founders identified by PCR using transgene-specific primers as described in Supplementary Material online. The number of transgene-positive/total potential embryonic founders was as follows: K5-sTAg: 11/92, K5-sTAgL142A: 5/18, and K5-sTAg91-95A: 11/122. Detailed analysis of sTAg embryo harvests is provided in Supplementary Table S1 online.
Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen- inducible Cre-ER(T) and Cre-ER(T2) recombinases.
) mice (kindly provided by Drs Pierre Chambon and Daniel Metzger) to generate K5-CreERT2;KLEsT (iK5;KLEsT) bitransgenic mice for analysis. Recombination leading to sTAg expression was induced in P21 mice by five daily oral gavage administrations of 75 mg kg-1 tamoxifen (Sigma-Aldrich, St. Louis, MO) resuspended in corn oil. KLEsT founder mice were crossed with C57BL/6J breeders (Jackson Laboratory, Bar Harbor, ME) to establish transgenic lines. All mice were housed and maintained according to University of Michigan institutional guidelines. Procedures involving animal experimentation were approved by the University Committee on the Use and Care of Animals, animal protocol #PRO00004440.
Tissue collection and immunostaining
All tissues were fixed overnight at room temperature in 10% neutral buffered formalin, transferred to 70% EtOH, processed, and paraffin embedded. For immunohistochemical staining, tissue was sectioned at 5 μm, deparaffinized, and rehydrated prior to antigen retrieval in boiling citrate-based buffer (0.01 mol l-1 citric acid, pH 6.8). Endogenous peroxidases were quenched with 3% H2O2, followed by blocking in 5% goat serum and incubation with primary antibodies (see Supplementary Material online for details). Bound antibodies were detected with the Vector M.O.M. peroxidase or fluorescein Immunodetection Kits (Vector Laboratories, Burlington, CA), using SigmaFast diaminobenzidene as a peroxidase substrate or AlexaFluor594 (Jackson ImmunoResearch, West Grove, PA) for immunofluorescence. Nuclei were counterstained with hematoxylin followed by Permount (Fisher Scientific, Fair Lawn, NJ) mounting or immunofluorescence visualized with ProLong Gold Antifade Reagent with DAPI (Life Technologies, Grand Island, NY).
Immunoblotting and immunoprecipitation
Epidermal lysates were prepared by mechanical homogenization in RIPA buffer supplemented with HALT phosphatase inhibitor cocktail (Thermo Scientific, Rockford, IL) and Complete mini protease inhibitor cocktail (Roche, Manheim, Germany) followed by protein quantification using standard Bradford method with Bio-Rad Protein Assay dye reagent (Bio-Rad Laboratories, Hercules, CA). For immunoprecipitation, 500 μg of pre-cleared protein lysate was incubated with 5 μg of primary mouse 2t2 antibody overnight at 4 °C followed by binding to Protein G Sepharose beads (GE Healthcare, Sweden). Beads were centrifuged, washed, and the pellet dissolved in Laemmli buffer. Supernatants were separated on 4–20% or 12% gradient SDS-polyacrylamide gels followed by transfer to Immobilon-P membranes (Millipore, Billerica, MA). Antibody details are listed in Supplementary Material online. Detection was carried out with SuperSignal West Pico or Femto chemiluminescent substrates (Thermo Scientific).
Quantification of epidermal thickness
Epidermal thickness at each site (tail, ear, volar, and snout) was measured as an average from four fields in three independent mice. Statistics were performed using an unpaired two-tailed Student’s t test.
ACKNOWLEDGMENTS
We thank Joanna Pero, Natalia Loaiza, and Ehab Nazzal for additional technical assistance, Eric Fearon for insightful comments on the manuscript, and Chris Buck, Pierre Coulombe, Daniel Metzger, Pierre Chambon, and José Jorcano for providing mice and/or reagents. We gratefully acknowledge Wanda Filipiak and Galina Gavrilina of the Transgenic Animal Model Core of the University of Michigan’s Biomedical Research Core Facilities for production of transgenic mice. This work was supported by a Research Career Development Award (MEV), Dermatopathology Research Career Development Award (PWH), and Clinical Career Development Award in Dermatologic Surgery (CKB), each from the Dermatology Foundation; the Helen L. Kay Charitable Trust; the Ronald P. and Joan M. Nordgren Cancer Research Funds (AAD); and the National Institutes of Health, through the University of Michigan’s Cancer Center Support Grant (CA046592), the University of Michigan Gastrointestinal Peptide Research Center Grant (DK34933), and R01s CA087837, AR045973, and R21 CA183084 (AAD).
Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen- inducible Cre-ER(T) and Cre-ER(T2) recombinases.
Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system.
37226-2&id=gr1.jpg){kind=link}
37226-2&id=gr2.jpg){kind=link}
37226-2&id=gr3.jpg){kind=link}
37226-2&id=gr4.jpg){kind=link}
37226-2&id=gr5.jpg){kind=link}
37226-2&id=gr6.jpg){kind=link}